Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 3/20 | 0.49 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.45 |
| ▸ | CHUK | O15111 | 1/20 | 0.44 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | PRKACA | P17612 | 1/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
| ▸ | CLK2 | P49760 | 1/20 | 0.44 |
| ▸ | PRKX | P51817 | 1/20 | 0.44 |
| ▸ | PRKG2 | Q13237 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23791472 | 1.00 | SLC6A2 (0.50) | SLC6A2SLC6A4CHRNB2CHRNA4HTR2C | |
| SCHEMBL23632246 | 1.00 | SLC6A2 (0.50) | SLC6A2SLC6A4CHRNB2CHRNA4HTR2C | |
| SCHEMBL28577996 | 0.90 | CHRNB2 (0.51) | SLC6A2SLC6A4CHRNB2CHRNA4HTR2C | |
| SCHEMBL23166823 | 0.90 | CHRNB2 (0.51) | SLC6A2SLC6A4CHRNB2CHRNA4HTR2C | |
| SCHEMBL28590003 | 0.90 | CHRNB2 (0.51) | SLC6A2SLC6A4CHRNB2CHRNA4HTR2C | |
| SCHEMBL656128 | 0.90 | HRH1 (0.59) | SLC6A2SLC6A4HTR2CHRH1ROCK1 | |
| Hydrochloric Acid SCHEMBL2249443 | 0.88 | HRH1 (0.58) | SLC6A2SLC6A4HTR2CHRH1ROCK1 | |
| Hydrochloric Acid SCHEMBL2332525 | 0.87 | HRH1 (0.56) | SLC6A2SLC6A4HTR2CHRH1ROCK1 | |
| SCHEMBL3004210 | 0.86 | SLC6A4 (0.49) | SLC6A2SLC6A4CHRNB2CHRNA4HTR2C | |
| SCHEMBL13703553 | 0.85 | HRH1 (0.54) | SLC6A2SLC6A4HTR2CHRH1PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113072476-B | ROR gamma t inhibitor and preparation method and application thereof | 广东东阳光药业股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-113072542-B | ROR gamma t inhibitor and preparation method and application thereof | 广东东阳光药业股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| US-20230121086-A1 | RORgT INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2023-04-20 | — | — | US | disclosed |
| US-20230067159-A1 | ROR-GAMMA-T INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2023-03-02 | — | — | US | disclosed |
| EP-4089080-A1 | RORyT INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2022-11-16 | — | — | EP | disclosed |
| EP-4089079-A1 | ROR GAMMA T INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2022-11-16 | — | — | EP | disclosed |
| WO-2021139599-A1 | RORγT INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 东莞市东阳光新药研发有限公司 | 2021-07-15 | — | — | WO | disclosed |
| WO-2021139595-A1 | RORγT INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 东莞市东阳光新药研发有限公司 | 2021-07-15 | — | — | WO | disclosed |
| CN-113072476-A | ROR gamma t inhibitor and preparation method and application thereof | 广东东阳光药业有限公司 | 2021-07-06 | — | — | CN | disclosed |
| CN-113072542-A | ROR gamma t inhibitor and preparation method and application thereof | 广东东阳光药业有限公司 | 2021-07-06 | — | — | CN | disclosed |
| WO-2012076063-A1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM S.P.A. (IT) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012076063-A1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM S.P.A. (IT) | 2012-06-14 | — | — | WO | disclosed |
| US-7790763-B2 | Substituted phenyl methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790763-B2 | Substituted phenyl methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790763-B2 | Substituted phenyl methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-09-07 | — | — | US | disclosed |
| EP-1843767-B1 | 2,5-DISUBSTITUTED PHENYL METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS. | HOFFMANN LA ROCHE (CH) | 2009-07-08 | — | — | EP | disclosed |
| EP-1843767-B1 | 2,5-DISUBSTITUTED PHENYL METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS. | HOFFMANN LA ROCHE (CH) | 2009-07-08 | — | — | EP | disclosed |
| EP-1843767-A1 | 2,5-DISUBSTITUTED PHENYL METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS. | F. Hoffmann-Roche AG (CH) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006077026-A1 | 2, 5-DISUBSTITUTED PHENYL METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-I) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRY DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-07-27 | — | — | WO | disclosed |
| US-20060160788-A1 | Substituted phenyl methanone derivatives | HOFFMANN-LA ROCHE INC. | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160788-A1 | Substituted phenyl methanone derivatives | SLC6A5, SLC6A1, SLC1A1 | SLC6A2 39/4885SLC6A4 26/4885CHRNB2 975/4885 |
| US-20230067159-A1 | ROR-GAMMA-T INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF | RORC, RORB, RORA | SLC6A2 4870/4885SLC6A4 4879/4885CHRNB2 2172/4885 |
| US-20230121086-A1 | RORgT INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF | RORC, RORB, RORA | SLC6A2 4816/4885SLC6A4 4868/4885CHRNB2 3325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.